Abstract
Vitamin D is essential in bone mineralization and calcium homeostasis, and an increasing body of evidence suggests that vitamin D may be important for maintaining extraskeletal health, including having beneficial effects on cardiometabolic outcomes. Vitamin D deficiency is widespread, but the role of vitamin D in the metabolic syndrome is not fully elucidated. In this review we summarize data from observational studies and randomized controlled trials on the relation between vitamin D and the metabolic syndrome and its components. A large number of observational studies suggest a relationship between low levels of 25(OH)D and the metabolic syndrome or its individual clinical features. Randomized controlled trials of vitamin D supplementation addressing aspects of the metabolic syndrome have yielded inconsistent results, and many studies suffer from methodological limitations. There is an urgent need for large, well-designed randomized controlled trials with relevant endpoints. Until definitive results from such studies are available, caution should be taken towards the use of vitamin D-supplementation for disorders other than musculoskeletal system. New molecular biological techniques elucidating the interaction between the active vitamin D derivatives and target genes represent a promising approach to more precise knowledge about new biomedical function, which also might shed light on the complex metabolic syndrome.
Keywords: Cholecalciferol, glucose metabolism, hypertension, insulin resistance, lipids, metabolic syndrome, obesity, review, vitamin D, VDR, 25(OH)D
Current Vascular Pharmacology
Title:Vitamin D and the Metabolic Syndrome
Volume: 11 Issue: 6
Author(s): Hanne L. Gulseth, Ingrid M.F. Gjelstad, Kare I. Birkeland and Christian A. Drevon
Affiliation:
Keywords: Cholecalciferol, glucose metabolism, hypertension, insulin resistance, lipids, metabolic syndrome, obesity, review, vitamin D, VDR, 25(OH)D
Abstract: Vitamin D is essential in bone mineralization and calcium homeostasis, and an increasing body of evidence suggests that vitamin D may be important for maintaining extraskeletal health, including having beneficial effects on cardiometabolic outcomes. Vitamin D deficiency is widespread, but the role of vitamin D in the metabolic syndrome is not fully elucidated. In this review we summarize data from observational studies and randomized controlled trials on the relation between vitamin D and the metabolic syndrome and its components. A large number of observational studies suggest a relationship between low levels of 25(OH)D and the metabolic syndrome or its individual clinical features. Randomized controlled trials of vitamin D supplementation addressing aspects of the metabolic syndrome have yielded inconsistent results, and many studies suffer from methodological limitations. There is an urgent need for large, well-designed randomized controlled trials with relevant endpoints. Until definitive results from such studies are available, caution should be taken towards the use of vitamin D-supplementation for disorders other than musculoskeletal system. New molecular biological techniques elucidating the interaction between the active vitamin D derivatives and target genes represent a promising approach to more precise knowledge about new biomedical function, which also might shed light on the complex metabolic syndrome.
Export Options
About this article
Cite this article as:
Gulseth L. Hanne, Gjelstad M.F. Ingrid, Birkeland I. Kare and Drevon A. Christian, Vitamin D and the Metabolic Syndrome, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113119990169
DOI https://dx.doi.org/10.2174/15701611113119990169 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology Editorial [Hot Topic: Stroke Prevention (Guest Editors: T. Tatlisumak, K. Rantanen and M. Fisher)]
Current Drug Targets Carbon Monoxide and the Brain: Time to Rethink the Dogma
Current Pharmaceutical Design Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Nutritional Control, Gene Regulation, and Transformation of Vascular Smooth Muscle Cells in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Inflammation, Oxidative Stress and Metabolic Syndrome: Dietary Modulation
Current Vascular Pharmacology Pharmacogenomics
Current Drug Metabolism Editorial (Hot Topic: Renin-Angiotensin System in Neuronal Disease)
Current Hypertension Reviews Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies
Current Drug Targets The Importance of Novel Inflammatory Biomarkers in Renal Disease
Current Medicinal Chemistry Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Clinically Significant Proteinuria Following the Administration of Sirolimus to Renal Transplant Recipients
Drug Metabolism Letters Mechanisms of Endothelial Dysfunction: Clinical Significance and Preventive Non-Pharmacological Therapeutic Strategies
Current Pharmaceutical Design Antihyperglycemic Effect of the Moroccan Collard Green (<i>Brassica oleracea</i> var. <i>viridis</i>) in Streptozotocin-Induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Calcific Aortic Valve Disease and Hypertension
Current Hypertension Reviews Anti-hypertensive Effects of Diminazene Aceturate: An Angiotensin- Converting Enzyme 2 Activator in Rats
Protein & Peptide Letters Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism Desmopressin 30 Years in Clinical Use: A Safety Review
Current Drug Safety Maternal and Fetal Outcomes in Iranian Patients with Systemic Lupus Erythematosus: A Five-Year Retrospective Study of 60 Pregnancies
Current Rheumatology Reviews